"We are very pleased that all of our challenged patents have been fully upheld in this ruling", says CEO of Pronova BioPharma ASA Morten Jurs.

"We have been confident in our intellectual property rights and have spent considerable resources on defending our patents in the USA. We look forward to continue building the Lovaza(TM) brand in our largest market". The US market represents approximately half of total revenues.

The Court found Pronova's patent claims are valid, enforceable and would be infringed by Teva Pharmaceutivals USA, Inc. ("Teva") and Par Pharmaceutical Inc. ("Par"). In a written ruling, the Court found: "that Pronova has met its burden to prove infringement of the '667 and '077 patents by a preponderance of the evidence; defendants have not proven that the asserted claims of either patent are invalid by clear and convincing evidence; and defendants have not proven, by clear and convincing evidence, that either patent is unenforceable due to inequitable conduct."

The Lovaza patents are owned by Pronova and licensed to GlaxoSmithKline in the United States and Puerto Rico, and cover compositions and methods of using omega-3 fatty acids. The '667 patent expires in April 2017 and the '077 patent expires in March 2013. Pronova, via its wholly owned subsidiary Pronova BioPharma Norge AS, filed the patent infringement lawsuits against Teva and Par in April 2009.

About Pronova BioPharma

Pronova is a global leader in research, development and manufacture of lipid therapies derived from nature.

The group's first commercialised product, Omacor/Lovaza, is branded in a number of countries (57) throughout Europe, Asia and in the USA. End-user sales has grown rapidly in all international  markets and the annual run rate at 31 December 2011 reached USD 1 380 million, according to IMS Health. The product is the first EU- and FDA-approved omega 3-derived prescription drug.

Marketing and distribution of Pronova's key product is currently licensed to both local and global pharmaceutical companies.

The company is in the process of developing several new, patentable lipid derivatives. The most advanced lipid derived pharmaceutical programme is in the area of combined dyslipidemia, the abnormal concentration of lipids and lipoproteins in the blood, for which the company has a product, PRC-4016, in clinical trials.

Pronova has also announced plans to enter the consumer healthcare and clinical nutrition markets, enabling the company to further leverage its position as the world's largest manufacturer of high grade omega-3 derived products.

Pronova's headquarters are located at Lysaker in Norway, while production takes place at state-of-the-art manufacturing facilities at Sandefjord in Norway and in Kalundborg, Denmark. The company's shares are listed on Oslo Børs with the ticker code PRON.

Additional information is available on www.pronova.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

distributed by